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Thromboxane Az  (TXA2)  is an unstable,  yet biologically active, byproduct of a 
biosynthetic pathway which is initiated by the action of cyclo-oxygenase upon the 
polyunsaturated  fatty  acid  substrate,  arachidonic  acid  (1).  Another  limb  of this 
pathway leads to generation of stable prostaglandins. TXA2 is derived from the cyclic 
endoperoxides, prostaglandin (32 (PGG2) and prostaglandin Hz (PGH2). After a half- 
life  of only  30-40  s  in  aqueous  media  at  physiologic  temperature  and  pH,  it  is 
primarily transformed to the biologically inactive and stable thromboxane B2 (TXB2) 
(1). At nanomolar concentrations, TXA2 causes rapid, irreversible platelet aggregation 
and  the  associated  platelet  release  reaction  (1,  2);  it  also  provokes contraction of 
vascular  and  tracheal  smooth  muscle  (3).  Its  role in  provoking other phenomena 
associated with inflammation is currently under investigation (4). Since polymorpho- 
nuclear  leukocytes  (PMN)  of human  peripheral  blood  have  recently been  shown 
capable of synthesizing stable prostaglandins (of the E and F series) upon exposure to 
phagocytic stimuli (5), we have examined whether generation of thromboxanes occurs 
under similar conditions.  For these studies we have employed a  sensitive radioim- 
munoassay for the stable end-product, TXB2 (6). The formation of [a4C]TXB2  from 
[a4C]arachidonic acid in suspensions of PMN was  demonstrated by means of thin- 
layer radiochromatography (TLC), radio-gas chromatography, and mass spectrome- 
try. 
Materials and Methods 
Preparation of PMN Suspensions and Serum-Treated Zymosan  (STZ).  Leukocyte suspensions 
containing approximately 98:1:  1% PMN were prepared from heparinized (10 U/ml) venous 
blood obtained from healthy adult donors by employing Hypaque/Ficoll gradients (7) and 
dextran sedimentation. Erythrocytes  were removed by hypotonic lysis. The cells were suspended 
in phosphate (10 mM)-buffered saline, pH 7.4, supplemented with 0.6 mM CaCI2 and 1.0 mM 
MgClz. This buffer was used throughout. The platelet: PMN ratio in the cell suspensions was 
generally in the range of 1:10. This ratio never exceeded 2:5. For some experiments, PMN were 
obtained from a patient with untreated idiopathic thrombocytopenia  whose peripheral platelet 
count was  16,000/mm s. The platelet:PMN ratio in the cell suspension  prepared from this 
patient's blood was  less than  1:40. For other experiments,  suspensions  of washed  platelets 
(containing fewer than 1 ×  106 PMN/ml) were prepared from normal platelet-rich plasma (8). 
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STZ  was  prepared  as  previously described  (9)  and  suspended  in  buffer at  concentrations 
ranging from 5.0 to 50 mg/ml. 
Reaction Mixtures and Radioimmunoassay.  Portions of tell suspensions containing 1 ×  107 PMN 
were dispensed into 12  ×  75-mm polypropylene tubes (BioQuest, BBL, and Falcon Products, 
Cockeysville, Md.)  before addition of appropriate compounds and stimuli. Some cells were 
preincubated  with  cytochalasin B  (5.0  #g/ml)  (ICI  Research  Laboratories, Alderley Park, 
Cheshire, England) in 0.1% dimethyl sulfoxide (Matheson Gas Products, East Rutherford, N. 
J.) at 37°C for 10 rain. Further incubations at 37°C were terminated by addition ofindometh- 
acin (5  X  10  -5 M)  (Sigma Chemical Co., St. Louis, Ms.) and by placing the tubes in dry ice- 
acetone. Samples were stored at -  70 oC before radioimmunoassay. Radioimmunoassay of TXBz 
was  performed  as  previously described  by  GranstrSm  et  al  (6).  Results  are  expressed  as 
picograms/106 PMN. 
TLC, Radio-Gas Chromatography, and Mass Spectrometry.  Reaction mixtures for analysis by TLC 
contained 5-8 X  10  ~ PMN. These were preincubated for 2 min at 37°C before addition of 0.03 
mM (1.5 #Ci) [14C]arachidonic acid (The Radiochemical Centre, Amersham, England), appro- 
priate compounds and stimuli (STZ, 5.0 mg/10  ~ PMN).  Further incubations at  37°C  were 
terminated after  15  min by adding  10 ml cold ethanol. Crude incubation/ethanol mixtures 
were diluted with unequal  volume of H20,  acidified to pH  3.0,  and extracted twice with 
diethyl-ether. The combined organic phases were washed with H20 until neutral and dried 
with MgSO4. The ether was evaporated and the residue treated with diazomethane in methanol 
before separation with ether:methanol (99:1) on TLC plates coated with Silica gel G (0.25 mm) 
(Analtech, Inc., Newark, Del.). A  Berthold Diinnschichtscanner II was employed to identify 
radiolabeled fractions on the TLC plates. 
Compounds that on TLC appeared at the same Rf value as the methyl-ester of a reference 
standard of TXB2 (i.e., between methylesters of PGF~ and PGAI) were extracted with hexane. 
The yields were 0.8-2.1 ng/106 PMN. Hexane was removed and the samples were dissolved in 
0.2 ml pyridine containing 5.0 mg of methoxyamine hydrochloride (Eastman Organic Chemi- 
cals Div., Eastman Kodak Co., Rochester, N. Y.). The solutions were stored in a stoppered test 
tube overnight in a  desiccator before addition of 20 lal of trimethylchlorosilane and 40 ~1 of 
hexamethyldisilazane (Merck, Sharp & Dohme, Quebec, Canada). After an additional 1 h in 
the  desiccator,  the  samples  were  evaporated  to  dryness,  extracted  with  ether  and  finally 
dissolved in hexane before injection into the radio-gas chromatograph  (Barber Colman Co., 
Rockford, Ill.). Chromatography was performed at a temperature of 225°C with a 6.0 mm  X 
185 cm column packed with 1.0% SE 30 on Chromosorb W 80/100. Carrier gas (He) flow was 
60 ml/min. The flash heater and detector were kept at a temperature 15°C above that of the 
column  (10).  The gas chromatogram of the methoxyamine trimethylsilyl derivatives of the 
samples showed characteristic peaks at the equivalent chain length C-24.9. 
Mass spectra of samples (methoxyamine trimethylsilyl derivatives) from several incubations 
were obtained with a combined gas chromatograph-mass spectrometer (LKB 9000)  equipped 
with a  210-cm long 1.0% SE 30 column on Chromosorb W  100/120.  Column inner diameter 
was 3 mm and the curler gas (He) flow was 20 ml/min. 
Other Compounds and Reagents.  Unlabeled arachidonic acid was purchased from  Nu-Chek 
Co., Elysian, Minn. TXBz (as a standard) was prepared according to Hamberg and Samuelsson 
(11). PGE~ and PGA1 were kindly supplied by Dr. G. L. Bundy of the Upjohn Co., Kalamazoo, 
Mich.  Indomethacin  was  dissolved  in  ethanol  before  being  diluted  in  buffer.  The  final 
concentration of ethanol in the reaction mixtures never exceeded 0.05%. All solvents were either 
reagent grade (Eastman Kodak Co.) or Fisher-certified (Fisher Scientific Co., Pittsburgh, Pa.). 
Some were redistilled before use. 
Results 
PMN  incubated for up  to 60 min  in buffer alone generated minimal amounts of 
TXB2  (15.7  ±  1.9  pg/106  PMN,  n  ---  10).  However,  when  PMN  were  exposed to 
STZ,  which  they ingest avidly, up  to  10-fold increments  in TXBz  generation were 
observed. The mean  ±  SE for  13 experiments was 65.8  :t:  12.2  pg/10  s  PMN.  This 
response varied with the particle-to-cell ratio and with  time. Representative experi- GOLDSTEIN ET AL.  BRIEF DEFINITIVE REPORT  789 
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FIG.  1.  Thromboxane B2 generation by human PMN exposed to STZ: (A) versus duration of 
incubation, (13) versus concentration of STZ. Reaction mixtures contained 1 X 10  7 PMN in a 1.0- 
ml vol. 
TABLE  I 
Generation of Thromboxan¢ B2 (TXB2) by Human PAIN 
PMN expmed to:  TXB=* 
(n)  picog~/ lO  ~ PMN/15 rain 
Buffer alone  (10)  15.7 ±  1.9 
+  Indomethacin (5  X  1O  -s M)  (6)  9.9 3=  1.4 
Cytochalasin B  +  buffer:l:  (6)  16.2 ±  4.2 
+  indomethacin  (4)  10.8 3=  1.8 
STZ (2.0 mg/ml)  (13)  65,8  3=  12.2 
+  Indornethacin  (9)  13.5 3= 0.9 
Cytochal~in B  +  STZ  (9)  59.9  +  3.4 
+  lndomethacin  (5)  13.5 "4" 1.4 
* TX]~ measured by radioimmunoassay. Mean  3= SE. n -  number of experiments. 
:~ PMN were preincubated with cytochalasin B (5,0/~g/ml) for 10 rain at 370C. 
ments are shown in Fig.  1.  Maximum TXB2 generation usually occurred before  15 
min and an almost linear response was noted with concentrations of STZ between 0.5 
and 5.0 mg/ml. 
To  determine  whether  phagocytosis  was  a  prerequisite  for  TXB2  generation, 
experiments were performed employing the fungal metabolite, cytochalasin B. Cyto- 
chalasin B-treated PMN are unable to ingest particles such as STZ but nevertheless 
increase  their  oxidative  metabolism  and  degranulate  (release  lysosomal enzymes) 
upon  contact  of the  particles  with  their  cell  surfaces  (9,  12).  PMN  treated  with 
cytochalasin  B  and  then  exposed  to  STZ  generated  amounts  of TXB2  that  were 
comparable to amounts generated by normal cells (Table I). Generation of TXB2 by 
both normal and cytochalasin B-treated PMN in response to stimulation was inhibited 
appropriately by the cyclo-oxygenase inhibitor, indomethacin  (1, 2)  (Table I). Indo- 
methacin neither interfered with particle-to-cell contact nor with other responses of 
these cells to surface stimulation (i.e., lysosomal enzyme release and superoxide anion 
generation)  (data not shown). Furthermore, these concentrations of indomethacin did 
not influence the radioimmunoassay. 
Generation  of TXB~  in  these  experiments  could  not  be  attributed  to  platelet 
contamination of the PMN suspensions. Addition of washed platelets in 10-fold excess 
of normal platelet contamination did not influence the amount of TXB2 measured in 
reaction mixtures containing either resting cells or cells stimulated by the addition of 
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absence of added platelets (65.0  :t:  5.2 and 59.8  +  7.1 pg/106 PMN, respectively; n 
=  4).  Moreover, no  increase  in  TXB2  generation was observed  in  suspensions of 
washed platelets (without PMN) after addition of STZ. Zymosan has previously been 
shown to be incapable of provoking platelet aggregation in the absence of plasma 
(13).  Finally, generation of TXB2 by cells obtained from the patient with thrombo- 
cytopenia (54.6  pg/106 PMN, platelet:  PMN ratio <1:40)  was comparable to that 
measured when cells obtained from normal donors were exposed to identical amounts 
of STZ. 
The ability of PMN to form [14C]TXB2 from precursor [14C]arachidonic acid was 
demonstrated by means of TLC, gas chromatography, and mass spectrometry. The 
compounds which on radio-TLC showed the same Rt values as a reference standard 
of authentic TXB2 also appeared at the same retention as authentic TXB2 after radio- 
gas chromatography. When purified fractions of these samples were analyzed by gas 
chromatography-mass spectrometry, the mass spectra were in accordance with that of 
authentic TXB2  (11).  Characteristic peaks were at:  m/e 311,201  (base peak),  191, 
174, 173. Whereas some of the TXB2 demonstrated by these procedures could have 
been produced by the platelets that contaminated the PMN suspensions, considerably 
more TXB2 was recovered than could be accounted for by platelets alone. With a 
maximum platelet:PMN ratio of 2:5 and with a conversion of approximately 10% by 
platelets (11), the recovery of TXB2 produced by platelets alone should have been less 
than 0.4 ng/106 PMN in suspension. The amount of TXB2 actually isolated on TLC 
was in the range of 0.8-2.1 nanograms/106 PMN. 
Discussion 
Previous studies have established that human peripheral blood PMN are capable 
of producing stable prostaglandins of the E and F series when exposed to phagocytic 
stimuli (5). Recently, Higgs et al. (14) reported that homogenates of rabbit peritoneal 
PMN  that  had  been  permitted  to  ingest  killed  bacteria  generated  rabbit  aorta 
contracting activity (attributable to TXA2) when incubated with the prostaglandin 
endoperoxides, PGC~ or PGH2. TXA2 activity was not generated by homogenates 
prepared  from unstimulated cells.  It is of interest in this regard that  Smolen and 
Shohet (15) were able to demonstrate a  marked decrease during phagocytosis of the 
arachidonic acid content of phospholipids in the membranes of phagocytic vacuoles 
isolated  from  human  PMN.  In  another  recent  report  (16),  unstimulated  rabbit 
peritoneal  PMN  were  found  to  produce  monohydroxy acids  (by  the  action  of 
lipoxygenases) upon exposure to arachidonic acid and homo-7-1inoleic acid. 
We have previously demonstrated that intact, viable human PMN release and/or 
generate inflammatory materials and substances capable of provoking tissue injury 
when they encounter appropriate cell surface stimuli even in the absence of phago- 
cytosis. These include hydrolases and non-enzymatic substances ordinarily contained 
within azurophil or specific granules, as well as oxygen-derived free radicals (9). The 
studies reported here enable us to add thromboxanes to this list. The results of our 
studies demonstrate that stimulation of intact, viable human peripheral blood PMN 
leads to the generation of thromboxanes. Generation of TXB2 by PMN varied with 
the concentration of the stimulus employed and with time, but occurred independently 
of phagocytosis. The studies with cytochalasin B-treated PMN suggest that surface 
stimulation, in the absence of particle ingestion, is sufficient to provoke thromboxane 
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Summary 
Human peripheral blood polymorphonudear leukocytes were stimulated to gener- 
ate thromboxane B2 in a  time- and concentration-dependent  fashion upon exposure 
to serum-treated zymosan particles. Conversion by stimulated  PMN of [X4C]arachi- 
donic acid to [14C]thromboxane B2 was confirmed by thin-layer radioehromatography, 
radio-gas chromatography,  and  mass spectrometry. Generation of thromboxane B2 
was  independent  of platelet  contamination  and  could  be  inhibited  by  the  cyclo- 
oxygenase inhibitor, indomethacin. Cells rendered incapable of ingesting particles by 
treatment with cytochalasin  B  generated comparable amounts of thromboxane B2. 
These  results  suggest  that  human  peripheral  blood  polymorphonuclear leukocytes 
synthesize thromboxanes in response to surface stimulation independently of phago- 
cytosis. 
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